Suven Life Sciences Ltd

Issue Overview

• Type of issue and securities: Preferential Issue; Convertible Warrants.
• Total issue size: Rs 85,764.02 lakhs; no revision or undersubscription reported.
• Main objectives: clinical development through overseas subsidiary; drug discovery R&D.
• CAPEX for new R&D centre; General corporate purposes.

Utilisation of Proceeds

• Utilisation per offer document; no material deviations observed.
• 1(a) clinical development: end-quarter unutilised 12,757.13; utilised 27,242.87.
• During the quarter, utilised 8,364.23.
• 1(b) R&D: end-quarter unutilised 7,812.77; utilised 5,187.23.
• 1(c) CAPEX: end-quarter unutilised 15,039.06; utilised 4,960.94.
• 2 GCP: end-quarter unutilised 9,204.78; utilised 3,559.24.
• Total unutilised proceeds: 44,813.73.
• Transfer to subsidiary for operational ease: 28,994.05 lakhs.
• Deployment of unutilised proceeds: investments into mutual funds and fixed deposits; market value 46,828.97.
• Note: Gains on mutual funds excluded from monitoring scope.
• No lien created on proceeds.

Governance and Compliance

• Approvals: management undertaking and statutory auditor certificates; no material deviations.
• Delay in implementation: not applicable.
• Government/statutory approvals for objects: NA.
• There are no material events or information affecting viability reported.

General Corporate Purpose (GCP)

• GCP utilisation: 707.95; rent, office and R&D labs rent, employee benefits, power and fuel charges.
• Board approval for allocation: resolution dated 06 Aug 2026.

Annual Report access & KYC updates

• FY2025-26 Annual Report emailed to shareholders with registered email addresses.
• Shareholders without registered emails can access the Annual Report via the company website.
• Web path: https://www.suven.com/annualreports.aspx; QR code and site navigation available.
• Update PAN, KYC, and nomination details with DP/RTA; dividends/payments will be electronic upon update.
• Senior Citizens Investor Cell provides assistance via senior.citizen@kfintech.com; toll-free 1800 3094 006.
• RTA contact for queries: einward.ris@kfintech.com.

Overview

• Standalone BRSR report for FY2025-26 by Suven Life Sciences Limited.
• Primary activity: scientific research and technical services for pharma and life sciences, 100% turnover.
• Reporting boundary: standalone basis; exports account for about 70% of turnover.
• Markets served: national presence in 2 states and 4 international markets.

Key ESG Risks & Opportunities

• Clinical trials pose high cost and regulatory/delay risks; mitigation includes risk assessments, experienced team, recruitment strategies, DSMB oversight.
• Potential financial losses and delays to product launches from trial failures or non-compliance.
• Drug safety monitoring risk; mitigated by independent DSMB oversight and regulatory reporting.
• Opportunity: skilled human capital accelerates R&D and strengthens competitive edge.

Governance & Policy Highlights

• Board oversight of ESG with authority delegated to the Chairman for BRSR matters.
• Key policies: Code of Conduct, Anti-Bribery, Whistleblower, Human Rights, Grievance Redressal; Board approval.
• NABL/GLP/GCP aligned; references to NGRBC framework guiding ESG initiatives.
• Independent assurance: limited assurance on policies by J Sundharesan & Associates.
• No fines or enforcement actions reported in the period.

Social Responsibility & Workforce

• Total workforce: 142 permanent and 39 workers; female representation 28% (permanent) and 5% (workers).
• Board: 2 female directors out of 6; Key Management Personnel: 1 female out of 2.
• 100% health insurance coverage for all employees and workers.
• Well-being spend: 16.47% of revenue in FY2025-26.
• Return-to-work after parental leave: 100% for female permanent employees; adherence to inclusive policies.

Environmental Performance

• GHG emissions: Scope 1 45 tCO2e; Scope 2 1,295.76 tCO2e; total intensity 0.0000188 tCO2e per turnover.
• Energy use: total electricity 6,570 GJ; total fuel 65.7 GJ; total non-renewable energy 6,635.70 GJ; no reported renewables.
• Water: withdrawal 2,007.5 kl; consumption 1,807.5 kl; third-party water 2,007.5 kl.
• Waste: bio-medical 11.172 t; battery 0.175 t; total 11.347 t with incineration disposal.
• CETP treatment and STP-based water reuse; NABL accreditation; GLP/GCP compliance.

Stakeholder Engagement & Complaints

• Stakeholders: shareholders/investors, regulatory bodies, employees, customers, suppliers, local communities.
• Engagement channels: annual/quarterly results, website, email; need-based engagement for regulators and others.
• No complaints/grievances filed under the principles in FY2025-26; grievances policy available online.

Other Notable Metrics

• Sustainable sourcing: 90% of inputs sourced sustainably; 21% from MSMEs, 79% within India.
• Related party transactions: investments with related parties at 100%.
• Affiliations: member of three associations (Ph Pharmaceuticals Export Promotion Council, DSIR, NABL).
• Cybersecurity: Information Technology Security Policy in place; access via published policy link.
• CSR: CSR activity not applicable under the Companies Act; limited information available in this section.
• Assurance: limited assurance on policies; external provider: J Sundharesan & Associates.

AGM Details

• Date and time: 25 August 2026, 11:30 a.m. IST.
• Mode: VC / OAVM.
• Cut-off for e-voting: 18 August 2026.
• E-voting window: 21 Aug 2026 9:00 to 24 Aug 2026 17:00 IST.
• Remote e-voting and AGM join instructions provided.

Resolutions

• Item 1: Ordinary adoption of standalone and consolidated financial statements.
• Item 2: Ordinary re-appointment of Prof. Seyed E Hasnain as Director.
• Item 3: Ordinary RPT approving Dr. Madhavi Jasti appointment in overseas WOS; USD 400,000 initial.
• Item 4: Special re-appointment of Dr. Rao as Independent Director for five years from Jan 2027.
• Item 5: Special approval for variation in utilisation of preferential issue proceeds.

Related Party Transaction

• Dr. Madhavi Jasti to oversee medical affairs for overseas WOS; appointment from Sep 1, 2026.
• Remuneration USD 400,000 per annum initially; aggregate cap USD 1,000,000; payable by WOS.

Independent Directors

• Re-appointment of Dr. Vajja Sambasiva Rao as Independent Director for five years beginning 2027.

Fund Utilisation Variation

• Variation reallocates unutilised proceeds among approved objects; total proceeds unchanged.
• Monitoring Agency CRISIL to continue monitoring utilisation of unutilised proceeds.

Auditor Details

• Statutory Auditor: M/s Karvy & Co; tenure from 33rd to 38th AGM.
• Remuneration disclosure referenced in notes; no amount stated here.

Financials

• Standalone FY25-26 revenue from operations: 711.47 Lakhs; total income: 2,102.52 Lakhs
• Net loss: 5,486.28 Lakhs; EPS: (2.41)
• Consolidated net loss: 27,634.41 Lakhs; EPS: (12.13)
• Operating cash flow: -6,922.55; investing: -68,573.84; financing: 75,678.17 Lakhs
• Dividend: no dividend recommended for FY2025-26
• Authorised capital Rs 50 Cr; paid-up Rs 263.72 Cr; promoter 69.57%

Pipeline progress

• Masupirdine: 95% enrollment; topline data in Q2 2027; no safety issues
• Samelisant: Phase 3 in narcolepsy; Phase 2 completed; positive data
• Ropanicant: Phase 2b complete; Phase 3 initiation planned
• Tenaclidine: Phase 1 complete; preparing for Phase 2
• Usmarapride: Phase 2 PoC design finalised; initiation likely Q3/4 2026

Capital raise & use of proceeds

• Warrants: 6,40,02,999; Rs 134; Rs 857.64 Cr raised
• Conversion: 4,54,32,866 warrants converted; paid-up Rs 263.72 Cr
• Unutilised proceeds Rs 596.95 Cr; utilised Rs 260.69 Cr; receivable Rs 93.31 Cr
• Revised allocations: 475 Cr (1a); 130 Cr (1b); 125 Cr (1c); 127.64 Cr (2)
• Monitoring agency: CRISIL Ratings Limited

Governance & board

• Hasnain reappointment: rotation, 2027–2032, age 75
• Rao reappointment: Independent Director, 2027–2032
• Board meetings: 7 in FY25-26; ID meeting on 29 Jan 2026
• ESOP 2020: 3,22,800 options outstanding; Grant I 6,20,000; Grant II 3,45,000

Related party transactions

• Dr. Madhavi Jasti appointed full-time for overseas WOS; USD 400k p.a.
• Aggregate USD 1.0m; borne by overseas subsidiaries; approvals required

Audit & compliance

• Statutory auditor KARVY & Co; PPE audit trail not implemented; action planned
• Secretarial auditor DVM & Associates; LODR 19 issue; BSE waiver granted; NSE under consideration
• Independent directors declarations filed; governance disclosures completed

Shareholding & listing

• Promoter stake 69.57% via Jasti Property; 26.37 Cr shares
• Dematerialisation: 99.93%; authorised capital Rs 50 Cr; BSE 530239; NSE SUVEN
• AGM: 25 August 2026; VC/OAVM; e-voting Aug 21-24

Meeting Details

• Date: 17 July 2026.
• Event: Interaction with Investors & Analysts.
• Mode: In-person group/one-on-one meeting.
• Location: Mumbai.
• Participants: Company management.
• Purpose: Investor and analyst interaction.

AAIC-2026 participation

• Five scientific posters to be presented at AAIC-2026 (July 12-15, 2026, London).
• Masupirdine Phase-3 updates on agitation in Alzheimer's dementia to be showcased.
• Usmarapride Phase-2 development program updates to be presented.

Clinical programs and posters

• Evaluations of SUVN-I6107 (M1 PAM) in healthy subjects to be presented.
• SUVN-L1101142 (M4 PAM) poster on treatment of Alzheimer's disease and schizophrenia.
• Masupirdine Phase-3 updates covering trial population and progress.
• Usmarapride Phase-2 clinical development program updates.
• Efficacy of SUVN-N9503012 for cognitive/neurodegenerative disorders to be discussed.

Engagement and logistics

• Exhibit Booth #117 to discuss pipeline, development strategy, and partnering opportunities.